Newsletter Subject

ChatGPT: The Cure For Cancer?

From

paradigmpressgroup.com

Email Address

AltucherConfidential@mb.paradigmpressgroup.com

Sent On

Thu, Sep 21, 2023 09:16 PM

Email Preheader Text

Introducing Ray Blanco | Ray Blanco: ?This new technology won?t just create fortunes for investo

Introducing Ray Blanco [Altucher Confidential] September 21, 2023 [WEBSITE]( | [UNSUBSCRIBE]( Ray Blanco: ‘This new technology won’t just create fortunes for investors, it could even save your life.’ [Hero_Image] ChatGPT: The Cure For Cancer? By Ray Blanco External Advertisement Gov't Default! Your Bank Account Frozen! The Federal Reserve System Docket No. OP-1670 reveals a frightening plan to be rolled out. This plan gives the Fed the power to track and potentially even freeze your checking account. Not just the money you have in your account at the moment …But also every single check, withdrawal, deposit and transaction. [Click here to learn how to protect your money.]( [James Altucher] JAMES ALTUCHER James here. As you know, we have been diving into AI like crazy, and for good reason… The AI revolution is well underway, with companies in every industry racing to learn about AI programs. But this race isn’t only dominated by tech nerds… Almost every industry out there is looking to weave AI into its business model and turn the page to a more AI-centric story. Knowing this, we asked ourselves who would be the best person to partner with as AI starts to invade more and more industries. Ray Blanco answered the call… Ray is one of my colleagues here at Paradigm Press. He’s been publishing cutting-edge tech research for over a decade. Like me, Ray believes that revolutionary technology is the key to a bright future for humanity. But Ray is not only an astounding artificial intelligence expert… he also has tons of experience in biotechnology, information systems, space travel and more. That’s why we knew he would be a great person to partner with as we help you learn the best ways to profit in AI. Below, Ray talks about the intersection between AI and biotech, spelling out how AI will revolutionize medicine. If you’re an Altucher Investment Network subscriber, you should’ve already received this month’s full issue -- with Ray’s FULL article included -- via email today. Note: In consideration of Altucher Investment Network subscribers, we've redacted any references to any potential high-flying AI investment opportunities from the article below. Before you go there, though… I wanted to make sure you didn’t miss [my latest quick video.]( In it, I detail what I believe is one of the BIGGEST opportunities to profit in AI… Ever. [Click here to check it out.]( And read on. How ChatGPT Will Cure Cancer Ray Blanco [Ray Blanco] RAY BLANCO “How are you feeling?” It wasn’t the sort of question I would expect to have been asked at age 20 — especially since I’d always had good health. But one day, my girlfriend noticed a lump on my neck. The man asking me the question was tall and rugged, and concern marked his kind face. He looked the type to be wearing a football uniform and quarterbacking a touchdown drive. But he was wearing a lab coat and readying me to be zapped with beams of ionizing radiation. “I feel fine,” I told him. And I honestly did, as I’d only been getting radiation therapy at the cancer center for a couple of weeks, and wasn’t really feeling any side effects. That would come later. “Have you noticed any hair loss?” “Not really,” I answered. He leaned closer and noticed something on my shoulders. Then he reached behind my head and brought his hand back… full of my own hair. I was shocked. The radiation was already causing hair loss, something which I was told to expect, but it was still shocking. I had to change my hairstyle! They took measures to limit the radiation damage to the parts of my body with cancer cells. When I went under the radiation machine (which looked like something out of a Star Trek set), it was on a custom-formed foam body support, made to place me under the invisible beams as precisely as possible. They even tattooed me. The tiny tattoos I still carry were used to line me up precisely under the machine, so the radiation only went where it was needed. Despite several measures to limit radiation damage to the parts of my body with cancer cells, I would still experience burned skin, nausea, and vomiting. My worried mother kept trying to overfeed me but I often just couldn’t keep it down. Technology Saved My Life Fortunately, I’m still cancer free more than 20 years later. For some reason, Hodgkin’s lymphoma is particularly prevalent in young men. The technology that cured me hadn’t been around for very long at that time. Had I been born a decade or two earlier, I might not have survived. In the 1970s, it wasn’t even a 50/50 chance. By the 1990s when I was treated, the situation was much improved. Today, thanks to improving medical technology, Hodgkin’s is becoming a more survivable form of cancer. If it is dealt with early, when just at Stage 1, close to 90% of patients survive 5 years, and overall, the five-year survival rate has risen to almost 75%. That man and his team were some of the most wonderful, professional people I’d ever met. They saved my life! I haven’t seen them since, but sometimes I wonder how they’re doing all these years later. Most 20 year olds think they’re ten feet tall and bulletproof, but facing your mortality at that age changes your perspective on things. The experience also started my lifelong interest in medical technology, an interest I enjoy sharing with my readers by identifying exciting investable opportunities in the biotechnology space. Today, a new revolution in medical technology is in the making… Shocking U.S. Map Exposes $1.2T Opportunity [James Altucher]( Exactly 2,935 miles away from Wall Street lies [the biggest profit opportunity]( of your lifetime. A little-known opportunity which is creating an average of $32.8 BILLION in new wealth EVERY SINGLE DAY… That’s $1.2 trillion per year… And if you act fast, you have the chance to get in on the action starting right away. [Click here now for details](. The Great Generative AI Boom Of 2023 After OpenAI released a new version of its ChatGPT chatbot late last year, generative artificial intelligence software captured massive attention. The app itself is the fastest growing in internet history, building a 100 million strong user base in its first two and a half months. Currently, the chatbot app draws 25 million daily visits. And ChatGPT isn’t alone... Google’s Bard GPT, launched in March, draws 140 million visitors per month and is expected to surpass 1 billion visitors by the end of the year. But the enthusiasm goes beyond users accessing the benefits of the new technology on these new apps. Companies large and small see the potential of GPT AI and have gone into a frenzy investing in it. The hardware demand to support the intense computational workloads of large language models (of which ChatGPT is a notable example) has driven massive sales to AI-centric semiconductor companies like NVIDIA Corporation (NVDA), which has more than tripled this year and broken through a trillion-dollar valuation. “BioGPT” Generating New Cures ChatGPT is great stuff and a very useful tool. But the greatest good a new technology can give us is helping us to live longer healthier lives. Fortunately, the technology at the heart of ChatGPT isn’t just good for providing natural language answers via a chatbot. And generative AI can be trained on more than just text – which will revolutionize how we heal ourselves. The gleanings and insights that generative AI technology can give us are revolutionizing medicine and creating new cures, even including cancer. Our genetic profile makes us as unique as a snowflake, and how drugs interact with our bodies is unique. This is doubly true when it comes to cancer since the mutant cells that are the disease are also not just unique to a patient, but to themselves. Generative AI will be used to examine your genome and help devise a personalized treatment plan based on a predicted interaction with therapeutic drugs. Even with existing drugs, this improves the chances of survival. Machine vision AIs, trained with millions of medical scans, are already improving on humans when it comes to identifying the presence of cancer. In some cases, they have become so good that they can spot what specialists miss. Computer technology has been used to help discover new drugs for years, a field that I’ve followed closely. But older technology, often referred to as computational biology or bioinformatics, has usually been limited to searching through catalogs of existing compounds and trying to match them with disease targets as well as for modeling the biomechanics of human cells in order to better tailor new compounds to interact with them. Generative AI technology, on the other hand, is as the name suggests, capable of generating something entirely new. It can be trained on data, and then produce, that which doesn’t exist in any catalog or database anywhere, much like how ChatGPT can give you an original answer to a question about a business idea. Instead of being trained on human text and having letters or words supplying the tokens to create an intelligible string of text as a response to a query, a biology-focused generative bot can be trained on a biochemical database, learn the relationships between the building blocks of proteins and other compounds, and create entirely novel potential drugs no one has ever designed before. Just as ChatGPT can give you dozens of fresh ideas faster than any human can, an AI can do the same for new drugs. A biotech company called XXXXX, for example, has been using artificial intelligence tools to greatly accelerate the creation of new leads for treating disease. One AI tries to find potential cures from a huge library of millions of compounds, and another examines the potential of them working in a disease condition, like predicting how they will interact with a site on a cell membrane. But the company is upping its game with GPT technology. For example, XXXXX has built a chatbot into its discovery platform that helps researchers interact with it using natural language. But even more important, the company is using Nvidia hardware to power its generative AI platform to discover entirely new drugs. The AI “studies” a potential disease modifying drug target, then generates brand new drug candidates. The AI even predicts how well the candidates will bind to the target and how clinical trials will turn out. Developers take these leads and run from there. The process works at the incredible speeds of modern computer hardware – far faster than the old days when researchers had to painstakingly screen many drug candidates using test tubes. The old way of doing things would cost $400 million and take up to six years. One AI company claims it can do this for 10% of the cost and 33% of the time. The potential for generative AI to revolutionize the discovery of new drugs hasn’t been lost on Nvidia. In July, the semiconductor juggernaut invested $50 million into an AI biotech company called XXXXX. Naturally, the company plans to use Nvidia technology in order to train its AI models, which it can then provide to drug development companies for use as a service. But Recursion isn’t the only kid on the block... Dozens of biotechnology startups have launched over the past couple of years based on the potential of this AI technology when applied to healthcare. And companies are starting to go public, which creates exciting investment opportunities. In September AI drug developer XXXXXXXXXXXX raised hundreds of millions in a round that included mega-investors. I expect many of these companies will begin to go public in the months ahead, which will provide investors with exciting opportunities. Generative AI is a game changer for biotech stocks and things are just getting started. This new technology won’t just create fortunes for investors, it could even save your life. More soon. Stay tuned, Ray Blanco For Altucher Confidential Exposed: Biden’s 2022 mistake to cost him election? [James Altucher]( Will this ugly scandal doom Biden in 2024? In February 2022, [Joe Biden made the most dangerous mistake]( any President has made in the past 150 years. If it all plays out like Jim Rickards is predicting… Biden’s blunder will soon cost good Americans EVERYTHING. There’s still time to protect your money. But you can’t wait. [>>See Biden’s terrible mistake here<<]( [Paradigm]( ☰ ⊗ [ARCHIVE]( [ABOUT]( [Contact Us]( © 2023 Paradigm Press, LLC. 808 Saint Paul Street, Baltimore MD 21202. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher Confidential e-mail subscription and associated external offers sent from Altucher Confidential, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@altucherconfidential.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher Confidential is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your Altucher Confidential subscription, you can ensure its arrival in your mailbox by [whitelisting Altucher Confidential.](

EDM Keywords (290)

zapped years year would working wonder went well weeks wearing wanted vomiting usually used use upping unique type turn trying tripled treated trained train track tons told tokens time though things text technology team target tall take survived support suggestions subscribers submitting starting spot speak sort sometimes snowflake situation site since shoulders shocked share service seen security searching saved run rugged round rolled risen revolutionize reviewing response respecting researchers reply rent relationships references redacted recursion recommendation really readying readers read ray radiation race questions question query quarterbacking publications publication provide proteins protecting protect prospectus profit produce privacy printed president presence precisely power potential possible plays place perspective patient parts partner page overfeed overall order open one often nvidia noticed neck mortality month monitored money moment modeling miss millions might message match man mailing mailbox made machine lymphoma lump lost looking looked long line limited limit lifetime life licensed letters letter length learn leads launched know knew kid key keep july investors invade intersection interest interact insights improves important identifying humans humanity human however honestly help heart healthcare heal head hand hairstyle hair good gone go gleanings give get genome game following field feeling feedback fed facing experience expected expect exiting exit exist example examine even ensure end employees editors early dozens dominated diving disease discovery details detail default deemed decade dealt data cured cure creation creating create couple cost consulting consideration consent compounds company companies communication committed comes colleagues click check chatgpt chatbot change chances chance catalogs catalog cases candidates cancer bulletproof built brought broken born body bodies blunder biomechanics bioinformatics bind benefits believe begin becoming become beams average asked article arrival around applied app answered always also allow ai advised advertisements address account 90 33 2024 2023 1990s 1970s 10

Marketing emails from paradigmpressgroup.com

View More
Sent On

13/05/2024

Sent On

13/05/2024

Sent On

13/05/2024

Sent On

13/05/2024

Sent On

13/05/2024

Sent On

12/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.